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Inmany observational studies, the objective is to estimate the effect of treatment
or state-change on the recurrent event rate. If treatment is assigned after the
start of follow-up, traditional methods (eg, adjustment for baseline-only covari-
ates or fully conditional adjustment for time-dependent covariates) may give
biased results. We propose a two-stage modeling approach using the method
of sequential stratification to accurately estimate the effect of a time-dependent
treatment on the recurrent event rate. At the first stage, we estimate the pre-
treatment recurrent event trajectory using a proportional rates model censored
at the time of treatment. Prognostic scores are estimated from the linear predic-
tor of this model and used to match treated patients to as yet untreated controls
based on prognostic score at the time of treatment for the index patient. The final
model is stratified on matched sets and compares the posttreatment recurrent
event rate to the recurrent event rate of the matched controls. We demonstrate
through simulation that bias due to dependent censoring is negligible, provided
the treatment frequency is low, and we investigate a threshold at which correc-
tion for dependent censoring is needed. Themethod is applied to liver transplant
(LT), where we estimate the effect of development of post-LT End Stage Renal
Disease (ESRD) on rate of days hospitalized.
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1 INTRODUCTION
Recurrent events often serve as the basis for measuring treatment effects in observational studies. A reduction in out-
comes, such as repeated myocardial infarction or opportunistic infections, indicates that a treatment has a positive effect
on morbidity. Reductions in hospital admission rates among the treatment group would imply that lower morbidity as
well as reduced health care costs are associated with (or caused by) treatment.
Methods for analyzing recurrent events have been well described in the literature. Models have been developed that
condition on the event history1 or previous number of events.2 Marginal models, such as those of Lawless and Nadeau3
or Lin et al,4 allow for an interpretation of covariate effects on the recurrent event rate that does not require patients to
have similar event histories. Few papers to date have explored methods for using recurrent events as an evaluation of an
experimental treatment, with exceptions being Cook et al5 and Schaubel and Zhang.6
Treatment can be initiated after the beginning of follow-up, which occurs frequently in studies without randomization.
While some existing recurrent eventmethods can incorporate time-dependent covariates,7 these traditionalmethods often
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donot give interpretations that satisfy the research question of interest. In the settings often of interest, treatment initiation
depends on internal processes such as disease progression or the event history itself, violating the assumption of most
time-dependent recurrent event methods that time-dependent covariates be external.8 Ideally, we would begin follow-up
of an untreated patient, and after treatment initiation, we would compare the recurrent event rate to that of the same
patient had they remained untreated. This counterfactual experience is unobservable in practice, however.
In an attempt to compare each treated subject with their unobservable counterfactual treatment-free experience, this
article will extend the sequential stratification method described by Schaubel et al9 to the recurrent event setting. For
every subject treated at time s, subjects that are eligible to receive treatment at time s but do not are matched to the treated
subject. Each treated subjects's posttreatment recurrent event rate is compared to the averaged matched recurrent event
rate in what can be conceptualized as a subject-level experiment. Matched subjects that subsequently receive treatment
are censored from experiments for which they serve as controls, and begin their own experiment as the treated subject.
Note that, in every experiment, the comparison of interest begins at time s, such that recurrent events that occur in [0, s)
are not considered.
Schaubel et al9 proposed combininghard covariatematching and adjustment to ensure thatmatched subjectswere “sim-
ilar” to the treated subject in addition to the requirement that they remain untreated at time s. This method was proposed
in the univariate survival setting where failure times prior to treatment are not observed for treated subjects. However,
information regarding pretreatment recurrent event trajectories are available on all subjects in the setting described above.
Given that event history is a strong predictor of the recurrent event rate, we propose to leverage this information using a
two-stage modeling approach. In the first stage, we use a conditional rate model to describe pretreatment event trajecto-
ries for all subjects. We then use the linear predictor from this first stage model to caliper-match as yet untreated patients
to those receiving treatment at time s. The goal is to create a control group with an event trajectory similar to that which
the treated patient would have experienced had treatment not been available. The final model for the recurrent event rate
includes only the treatment effect and a measure of distance between the prognostic score of the treated subject and that
of the matched controls.
Themethod proposed is not restricted to “treatment” in the classical sense, and is in fact applicable to any state change.
Often, this state change is in the form of treatment such as initiation of new medication or performance of a procedure,
but this is not always the case. Diagnosis of disease or experience of a medical event such as injury could constitute a
state change for which comparing the recurrent event rate in the presence and absence of the state change is of clinical
or policy interest. This will be discussed further in relation to the application of the method to liver transplantation.
The remainder of this article proceeds as follows. In Section 2, we introduce the notation and proposed models and
describe the parameter estimation. Section 3 presents results of simulation studies to demonstrate the performance of the
treatment effect estimator inmoderate sized samples. An application to living donor liver transplant is described in Section
4 using data from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Some concluding
remarks are offered in Section 5.
2 METHODS
2.1 Notation
In the following, i represents subject (i = 1, … ,n), Ti is treatment time, with Ti ≥ 0, and Z∗i (t) represents the
time-dependent covariate for subject i. We assume for the purposes of this article that subjects treated at time Ti remain
treated for the duration of follow-up. The true number of events for subject i in [0, t] is defined as N∗i (t) = ∫ t0 dN∗i (u).
Event and treatment times are subject to independent right censoring by Ci, assumed to be administrative in this setting
without loss of generality. The number of observed events is given by Ni(t) = ∫ t0 I(Ci > u)dN∗i (u).
The number of pretreatment events in (0, t] is given by the counting process
N0i (t) = ∫
t
0
I(Ti > u)dN∗i (u). (1)
If patient i receives treatment at time s; ie, Ti = s, then the posttreatment event counter is defined as
N1i (t; s) = I(Ti = s)∫
s+t
s
dN∗i (u). (2)
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Note that itwill be our convention thatN(t; s) refers to the interval of length t, but starting at time s; a single time index, as in
the previously definedN0i (t), pertains to the (0, t] time interval. Correspondingly, we define an event counter representing
the events that would have been experienced in the absence of treatment, also beginning at time s,
N0i (t; s) = ∫
s+t
s
I(Ti > u)dN∗i (u). (3)
Note that (3) is the pretreatment event counter described in (1) but instead of (0, t] the counter N0i (t; s) tracks the patient
on (s, s + t]. For a subject eligible to receive the treatment at time s, (ie, I(Ti ≥ s)), if Ti = s, the counting process (2)
takes effect; if the treatment had not been available, process (3) takes effect. The subject is untreated on (0, s) under either
scenario to which (2) and (3) pertain.
Finally, we define a 0∕1 process for being observed to receive treatment,
NTi (t) = ∫
t
0
I(Ci > u)dI(Ti ≤ u). (4)
2.2 Proposed models
As described above, the goal of this method is to compare the posttreatment recurrent event mean to the corresponding
event mean under no treatment. We denote the mean of (2) by
𝜇1i (t; s) = E
[
∫
t
0
N1i (du; s)|Ti = s,Hi(s)
]
, (5)
whereHi(s) = {Z∗i (u),Ni(u), I(Ti > u), I(Ci > u); 0 ≤ u < s} represents the observed pretreatment history for subject i on
[0, s).
Similarly, in the absence of treatment, the mean of (3) can be written as
𝜇0i (t; s) = E
[
∫
t
0
N0i (du; s)|Hi(s),Ti > u
]
. (6)
Note, both models are partly conditional10-12 in the sense that they condition on the history up until time s as opposed to
s + t. We do not model either (5) or (6) directly, instead, our model of interest is given by
𝜇1i (t; s) = 𝜇
0
i (t; s) exp{𝛽⋆}, (7)
which can equivalently be expressed in terms of a rate function by
𝜇1i (dt; s) = 𝜇
0
i (dt; s) exp{𝛽⋆}. (8)
In this model 𝜇0i (t; s), the treatment-free mean number of events, is scaled up or down by exp{𝛽⋆} if subject i received the
experimental treatment at time s. The mean number of posttreatment events is then compared to the mean number of
treatment-free events after time s. It is conceivable that the treatment effect could depend on time since treatment, t, or
time of treatment, s, and this model can be extended to accommodate a time-dependent 𝛽⋆ in the form 𝛽⋆(t; ·), 𝛽⋆(·; s) or
𝛽⋆(t; s). Note that these different time-dependent forms of 𝛽⋆ could be any parametric function of time such as linear or
log-linear; time could also be categorized to examine the functional form of the time-dependent effect.
Since we cannot observe a patients' pretreatment experience once treatment is initiated, a patient treated at time s
will be compared to similar patients who did not start treatment at follow-up time s but were eligible to do so. Similar
to Schaubel et al,9 we use the concept that each treatment time initiates an “experiment,” in which the recipient of the
treatment is compared to “similar” treatment-eligible candidates. Note that “similar,” in this context, refers to current
status (ie, at time s) and history on [0, s). Eligibility for the comparison is defined as
ei(s) = I(Ti = s) + I(Ti > s),
ie, at time s, patient i either received the treatment or remained untreated.
Our method of estimating 𝛽⋆ from (8) involves a stratified analysis. Each treated patient generates a stratum, which
will include the index patient as well as similar treatment-eligible patients. Here, we define similar as both treatment
eligible at s, ei(s), and similar with regard to accumulated covariate and recurrent event history on (0, s],Hi(s). To quantify
each subject's history, we use a prognostic score13 based on the pre-treatment event rate, modeled using a time-dependent
proportional rates model,
d𝜇0i (t) = E
[
dN∗i (t)|Hi(t),Ti > t] = exp{𝜶T0Zi(t)}d𝜇0(t), (9)
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where the covariate Zi(t) is chosen to capture the pertinent components of the history, E[dN∗i (t)|Hi(t),Ti > t] =
E[dN∗i (t)|Zi(t),Ti > t]. Model (9) resembles the marginal Lin et al4 model but is more accurately interpreted as the condi-
tional Andersen-Gill1 model, due to the explicit dependence on the prior event history, a property avoided by Lin et al.4
The regression parameter𝜶0 from (9) can be computed by solving the unweighted Cox14 score equation. Due to the depen-
dence on internal covariates,8 elements of 𝜶0 are difficult to interpret. However, the purpose of this model is matching
similar subjects on [0, s), not interpretation. Note that, althoughwe have chosen amultiplicative model, other models (eg,
an additivemodelwith time-varying effects15)may provide better fit and are reasonable options. Note also that alternatives
to prognostic matching exist and will be discussed in Section 5.
The purpose of the prognostic score is to match patients that have similar pretreatment event rates, the rationale being
that previous event rate is the most important predictor of the current event rate. Unlike a propensity score, which uses
the treatment event rate tomatch subjects with similar probabilities of being treated, the prognostic score aims to compare
the effect of treatment on the event rate among subjects that were on the same trajectorywith respect to their pretreatment
event rate. The use of prognostic scores in conjunctionwith, or as a alternative to, propensity scores has been considered in
several reports16-19 and will be discussed later. Once the prognostic scores have been estimated, caliper matching is used to
assign untreated control subjects to a subject receiving treatment at time s. Caliper matching requires that the prognostic
scores of matched subjects be within a certain radius of the prognostic score of the index subject. Appropriate selection
of the caliper involves balancing the need for homogeneity within-stratum with the need to have an adequate number of
matches for each index subject. The discrepancy between prognostic scores for experimental subject j and control subject
i can be quantified through the subject-pair specific rate ratio,
𝜓i,𝑗(s) =
d𝜇0i (s)
d𝜇0
𝑗
(s)
= exp{𝜶T0 [Zi(s) − Z𝑗(s)]}.
Subject i is “similar” on [0, s) to subject j if |log𝜓i𝑗(s)| ≤ 𝜀, where 𝜀 > 0 is a predetermined constant.
Combining the eligibility indicators and prognostic scores, patient i is included in the stratum generated by patient j if
mij(s) = 1, where
mi𝑗(s) = ei(s)I(Ti > s)e𝑗(s)I(T𝑗 = s)I(|log?̂?i𝑗(s)| ≤ 𝜀),
with ?̂?i𝑗(s) = exp{?̂?T0 [Zi(s) − Z𝑗(s)]}. To account for the residual difference between patients i and j, we propose to adjust
for log?̂?i𝑗(s) in the final model. Incorporating the eligibility indicator and the prognostic score distance, the final fitted
model for the event mean for stratum j is then
𝜇⋆i𝑗 (t; s) = mi𝑗(s)𝜇
0
i (t; s) exp{𝛽⋆I(Ti = s) + 𝛽𝜓 log ?̂?i𝑗(s)}. (10)
In (10), j is the stratum (generated by patient j through Tj = s) and i is the patient within stratum. The model governs the
treated patient through the indicator I(Ti = s), which equals 1 if i = j. The vector of parameters to be estimated and the
corresponding covariates are given by
𝜷⋆𝜓 =
[
𝛽⋆
𝛽𝜓
]
Z⋆i (s) =
[
I(Ti = s)
log ?̂?i𝑗(s)
]
, (11)
such that model (10) can be rewritten as 𝜇⋆i (t; s) = mi𝑗(s)𝜇
0
i (t; s) exp{𝛽
T
⋆𝜓Z⋆i (s)}.
Subjects matched to the treated subject enter the experiment without receiving any treatment but could subsequently
receive treatment. If a matched subject receives treatment after time s they are censored from all experiments in which
they serve as controls and begin their own experiment as the index subject. This generally results in dependent censoring
since, although treatment can be considered random given Hi(s + t), the model for 𝜇⋆i𝑗 (t; s) from (10) only conditions
on Hi(s), the pretreatment history up to time s. While this could be addressed though Inverse Probability of Censoring
Weighting (IPCW),20-22 in this article, we consider treatments that are relatively rare, with rates small enough such that
bias due to dependent censoring is negligible. Section 3 will investigate through simulation treatment rates at which
dependent censoring needs to be addressed.
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2.3 Parameter estimation
To estimate 𝛽⋆ we define the pertinent risk set indicator for stratum j,
Yi𝑗(t; s) = mi𝑗(s)I(Ci > s + t){I(Ti = s) + I(Ti > s + t)}.
If, givenHi(s),matched subjects are randomly assigned to treatment after time s, the process
mi𝑗(s)∫
𝜏−s
0
Mi𝑗(du; s), (12)
where mij(s) is the matching indicator described above, Mij(du; s) = Yij(u; s){Ni(du; s) − 𝜇ij(du; s)}, and 𝜏 is chosen to
satisfy P(Ci ≥ 𝜏) > 0 and often set tomax{C1, … ,Cn}, would havemean zero. Asmentioned above, bias due to censoring
of subsequently treated controls is expected to be minimal in the setting of rare treatment, so we assume the condition
above holds.
Aggregating across subjects for the experiment occurring at time s produces the set of zero mean processes,
∑n
i=1
mi𝑗(s)∫
t
0
Mi𝑗(du; s), (13)
∑n
i=1
mi𝑗(s)∫
t
0
Z⋆i (s)Mi𝑗(du; s). (14)
We reorganize this system to solve implicitly for the baseline mean, 𝜇00(u; s) in (13), then substitute into (14). Then,
aggregating across all experiments yields the final estimating function for 𝜷⋆𝜓 ,
U(𝜷) =
n∑
𝑗=1
n∑
i=1 ∫
𝜏
0
mi𝑗(s)∫
𝜏−s
0
{Z⋆i (s) − Z⋆(u; s)}Ni(du; s)dN
T
𝑗 (s), (15)
where
Z⋆(u; s) =
∑n
𝓁=1m𝓁𝑗(s)Z⋆i (s) exp{𝜷
T
⋆𝜓Z⋆i (s)}∑n
𝓁=1m𝓁𝑗(s) exp{𝜷
T
⋆𝜓Z⋆i (s)}
.
Since U(𝜷) from (15) behaves asymptotically like a zero-mean estimating function, the solution to U(𝜷) = 0, denoted by
?̂?⋆𝜓 , should yield a consistent estimator of 𝜷⋆𝜓 .
2.4 Asymptotic properties and inference
We propose a variation of a method proposed by Lin et al4 to construct confidence bands for the mean function of the
proportional means model. The following regularity conditions are imposed:
(a)
[
Ni(t),Ci(t),NTi (t),N
D
i (t),Zi(t), 𝛾i
]
are independent and identically distributed.
(b) P(Xi ≥ 𝜏) > 0 for all i.
(c) Ni(𝜏) < ∞ for all i.
(d) E[I(Ti ≤ 𝜏)] > 0 for all i.
(e) Zi(t) is of bounded variation.
Under these conditions, it can be shown that
n1∕2(?̂? − 𝜷) = A−1(𝜷)n−1∕2
n∑
i=1
U i(𝜷) + o𝑝(1), (16)
where
U i(𝜷) = ∫
𝜏
0
mi(s)∫
𝜏−s
0
{Z⋆i (s) − z⋆(u; s)}dMi(s)dFT(s),
A(𝜷) = E
[
∫
𝜏
0
mi(s)∫
𝜏−s
0
{Z⋆i (s) − z⋆(u; s)}⊗2 exp{𝜷
TZ⋆i }dR
0
i (u; s)dF
T(s)
]
,
mi(s) is an indicator taking value 1 when patient i is matched in terms of prognostic score to the index patient treated at
time s and FT(s) is defined as above.
We the approximate the distribution of (16) using the sandwich form Â−1(?̂?)n−1∕2∑ni=1 Û i(?̂?)Û i(?̂?)T .
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3 SIMULATION STUDY
3.1 Simulations of proposed method
We conducted simulations to demonstrate the properties of the proposed estimator in moderate sized samples. For each
scenario ,we simulated 1000 subjects 500 times. In addition to the observed experience, the counterfactual, treatment-free
experience was generated for each subject to determine target values for 𝛽⋆, which, given the complex data structure,
were difficult to prespecify. Target values of 𝛽⋆ were determined by simulating observed and counterfactual experience
for 100 000 subjects 10 times and comparing each treated subjects' observed experience to their counterfactual experience.
Independent adjustment covariates Zi1 and Zi2 were generated to follow a Bernoulli(0.5) distribution. A longitudi-
nal covariate Z3 was generated to follow a U(0, 1) distribution at time 0 updated at every time unit with increment
Bernoulli(0.5) × U(0, 1). Starting at time 0, we generated a new event process based on the updated value of Z3 using a
frailty model with rate parameter Qid𝜇0 exp {𝛼1Zi1 + 𝛼2Zi2 + 𝛼3Zi3(t)}, where d𝜇0 = 10, 𝛼1 = 0.3, 𝛼2 = −0.1, 𝛼3 = 0.1,
where Qi was distributed Gamma with mean 1 and variance 0.5. Qi was used to induce additional correlation between
recurrent events and was capped at 2, the 90th percentile. Treatment times, TSi , were then generated to follow the hazard
𝜆T0 exp
{
𝛿1Zi1 + 𝛿2Zi2 + 𝛿3log(Ni(t−) + 1) + 𝛿4Zi3(t)
}
, where 𝛿1 = −0.2, 𝛿2 = 0.2, 𝛿3 = 0.2, 𝛿4 = 0.4. The recurrent event
times posttreatmentwere generated from rate parameterQid𝜇T0 exp
{
𝜙1Zi1 + 𝜙2Zi2 + 𝜙3log(Ni(Ti) + 1) + 𝜙4Zi3(t)
}
, where
𝜙1 = 0.3, 𝜙2 = −0.1, 𝜙3 = 0.2, 𝜙4 = 0.1.
Once the data were generated, prognostic scores representing pretreatment event trajectories were obtained from the
model d𝜇0i (t) = exp
{
𝛼01Zi1 + 𝛼02Zi2 + 𝛼03N0i (t
−) + 𝛼04Zi3(t)
}
. Subjects were matched if |log?̂?i𝑗| ≤ 0.025.
Parameters used in the simulation studies are as follows. For the pretreatment event rates, we set d𝜇0 = 3, 𝛼1 = 0.3, and
𝛼2 = −0.1 for the observed process and d𝜇0 = 6, 𝛼1 = 0.3, and 𝛼2 = −0.1 for the unobserved process. For the treatment
hazard, 𝜆T0 = 0.01, 𝛿1 = −0.2, 𝛿2 = 0.1, 𝛿3 = 0.2, and 𝛿4 = 0.5. Finally, for the posttreatment event rate, d𝜇T0 was given
values of 1, 1.5, 2, 3, 4, and 5, 𝜙1 = 0.3, 𝜙2 = −0.1, and 𝜙3 = 0.2. This resulted in values of 𝛽⋆ ranging from −0.725 to
0.714. In the simulated data 8% of the sample received treatment and the mean number of events was 20.7.
Results from the simulations are show in Table 1. Absolute bias ranged from 0.002 to 0.012. Empirical and asymptotic
standard errors were similar, and coverage probabilities ranged from 0.92 to 0.95, close to the target level of 0.95.
3.2 Investigation of dependent censoring
Recall that subjects are censored from strata in which they serve as controls if they subsequently receive treatment. Since
treatment depends on, among other things, the event history, this will result in dependent censoring in cases where
treatment is not rare. We used simulation to explore the point at which more common treatments result in substantial
bias. To do this, we used a similar set up to that of the previous section except that d𝜇T0 was set at 1 and 𝜆T0 took on
values of 0.01, 0.05, 0.15, and 0.3. This resulted in percentages of subjects treated ranging from 8% to 64%. Results of these
simulations are shown in Table 2.
As shown in Figure 1, increasing the proportion of subjects treated increases bias and decreases coverage probability.
At approximately one-third of subjects treated bias is at 0.03, and this almost triples to 0.086 when 64% of subjects are
treated, with increased bias resulting in lower coverage. Bias and coverage are similar from 8-24% treated, likely due to the
smaller absolute number of treated subjects. However, as the percentage of subjects treated increases, censoring of sub-
jects serving as controls due to subsequent treatment results in dependent censoring that begins to have a nonnegligible
TABLE 1 Results from simulations of n = 1000 subjects with varying
baseline pretreatment event rates
Scenario d𝜇10 𝛽⋆ Estimate Bias ESE ASE CP
1 0.3 −0.725 −0.731 −0.006 0.179 0.167 0.94
2 0.4 −0.553 −0.558 −0.005 0.171 0.165 0.95
3 0.5 −0.407 −0.410 −0.003 0.171 0.162 0.95
4 0.75 −0.111 −0.115 −0.004 0.172 0.157 0.94
5 1 0.113 0.111 −0.002 0.166 0.154 0.94
6 1.5 0.454 0.449 −0.005 0.166 0.149 0.93
7 1.75 0.592 0.585 −0.007 0.163 0.147 0.93
8 2 0.714 0.702 −0.012 0.166 0.145 0.92
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TABLE 2 Results from simulations with varying percent treated
Scenario % Treated 𝛽⋆ Estimate Bias ESE ASE CP
1 8% 0.714 0.706 −0.008 0.151 0.145 0.95
2 16% 0.693 0.681 −0.012 0.115 0.103 0.93
3 24% 0.674 0.651 −0.023 0.095 0.086 0.92
4 33% 0.650 0.620 −0.030 0.079 0.075 0.92
5 41% 0.626 0.585 −0.041 0.076 0.068 0.88
6 46% 0.603 0.553 −0.050 0.071 0.064 0.84
7 54% 0.578 0.518 −0.060 0.065 0.061 0.81
8 64% 0.536 0.450 −0.086 0.059 0.054 0.72
FIGURE 1 Bias and coverage probability with increasing percentage treated: The left y-axis shows bias and corresponds to the solid line.
The right y-axis shows coverage probability and corresponds to the dashed line
effect on the treatment effect. Given this trajectory, it is important to keep in mind that methods such as IPCW aimed at
correcting dependent censoring are not necessary only if the proportion of treated subjects relatively rare; however, once
the proportion of treated subjects becomes more prevalent weighting is necessary to correct bias.
4 APPLICATION TO LIVER TRANSPLANTATION
Development of End Stage Renal Disease (ESRD) post-liver transplant leads to increased patient morbidity and mortal-
ity, and places increased burden on heath care resources. We will use the proposed method to evaluate effect of ESRD
development post-liver transplant on the number of days hospitalized in the Adult-to-Adult Living Donor Liver Trans-
plantation Cohort Study (A2ALL). In this setting, the “treatment” of interest is development of ESRD, defined as initiation
of dialysis or kidney transplant post-liver transplant. As mentioned previously, the proposed method is generalizable to
time-dependent state changes such as development of post-LT ESRD. In this setting, we use time-dependent markers of
kidney function such as creatinine to estimate the hospitalization trajectory from the time of transplant to the develop-
ment of ESRD, and use these to match with patients on similar trajectories that do not develop ESRD. Comparing the rate
of days hospitalized for a patient that develops post-LT ESRD compared to the rate that would have been observed had
the patient not developed ESRD is a critical component to the estimation of the costs of post-LT care.
A2ALL is a multicenter NIH-funded consortium composed of 12 North American transplant centers. Potential living
donor liver transplant (LDLT) recipients transplanted between January 1, 1998, and January 31, 2014, were enrolled.
Retrospective and prospective data collection included posttransplant vital status and laboratory information as well as
hospitalization admission and discharge information. Data were supplemented from the Scientific Registry of Transplant
Recipients (SRTR). The SRTR data system includes data on all donors, wait-listed candidates, and transplant recipi-
ents in the United States; these data are submitted by the members of OPTN and have been described elsewhere. The
Health Resources and Services Administration (US Department of Health and Human Services) provides oversight for
the activities of the OPTN and SRTR contractors.
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There were 55 ESRD events out of 1447 transplanted patients in A2ALL. Median posttransplant follow-up time was
5 years, and the average number of days hospitalized per patient year was 14.9 for non-ESRD patients and 37.2 for ESRD
patients (median days 2.3 and 5.1, respectively). Hospitalization admissions that occurred after discharge from the trans-
plant hospitalization but before onset of ESRDwere used to build the prognostic model, which was adjusted for the event
history as well as other transplant and posttransplant time-dependent predictors. Results from the prognostic model are
shown in Table 3. Each additional day of hospitalization history was associated with a 2% increase in the rate of future
hospitalization days (P < .001).
Using prognostic scores derived from the model in Table 3, the distribution of prognostic score distance from index
patient with and without matching is shown in Figure 2. Prior to matching on prognostic score the range of distance
between the index subject and matched controls spans from −7.2 to 5.4, with 98% of matched controls within the interval
[−1.5, 3.5] from the index subject. When the 55 patients that developed ESRD posttransplant were matched to patients
that had not yet developed ESRD based on prognostic score, with all control subjects within ±0.02, the distribution of
score distance is much tighter around zero. The matching resulted in a median of 14 matches, with 6 (11%) of patients
that developed ESRD being excluded due to lack of matches.
The proposed method was then used to fit a stratified model to determine the effect of ESRD on the rate of days hospi-
talized (Model I) using model (10). The following traditional time-dependent proportional rates models were also fitted
where ESRD status was treated as a time-dependent predictor adjusted for the same predictors in the prognostic model
(Table 2).
𝜇i(t) = 𝜇0i (t) exp{𝜃III(Ti ≤ t) + 𝜷TZi(t)}, (17)
𝜇i(t) = 𝜇0i (t) exp{𝜃IIII(Ti ≤ t) + 𝜷TZi}. (18)
In the first model, model (17), additional time-dependent predictors thought to be associated with the progression to
ESRD were included, such as lab values and hospitalization history, while in second model, (18), only baseline, ie, at
transplant, values of these predictors were used. The results from all 3 models are shown in Table 4. In Model I, which
uses the proposed method, patients that develop ESRD have a rate of days hospitalized that is 2.9 times higher than
patients that have not yet developed ESRD. By contrast, results from Model II give a rate that is only 1.4 times higher for
TABLE 3 Prognostic model: pre-treatment rate of days hospitalized
Parameter Rate Ratio 95% Confidence Interval P Value
Recipient age at Transplant (ref=65+)
18−40 1.00 (0.95-1.06) .873
40−50 0.77 (0.73-0.81) <.001
50−55 0.79 (0.75-0.83) <.001
55−60 0.78 (0.74-0.82) <.001
60−65 0.87 (0.82-0.92) <.001
Recipient diagnosis: HCV 1.07 (1.04-1.10) <.001
African−American (ref=all others) 0.75 (0.71-0.79) <.001
Diabetes 0.89 (0.86-0.92) <.001
Ln(creatinine) (time-dependent) 1.31 (1.27-1.35) <.001
Ln(bilirubin) (time-dependent) 1.09 (1.07-1.10) <.001
Ln(albumin) (time-dependent) 0.36 (0.34-0.38) <.001
Donor age (ref=70+)
<18 0.64 (0.55-0.74) <.001
18−40 0.76 (0.67-0.87) <.001
40−50 0.78 (0.69-0.89) <.001
50−60 1.02 (0.90-1.16) .722
60−70 0.72 (0.63-0.83) <.001
DCD (ref=non-DCD) 1.33 (1.21-1.47) <.001
Regional (ref=Local) 1.32 (1.25-1.40) <.001
National (ref=Local) 1.41 (1.32-1.51) <.001
Split Liver 1.18 (1.08-1.29) <.001
Living Donor (ref=Deceased Donor) 0.96 (0.88-1.05) .397
Hospitalization History (per day) 1.02 (1.02-1.02) <.001
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FIGURE 2 Distribution of prognostic score distance from index patient with and without matching: The left panel shows the difference in
prognostic scores between the index patient and all potential controls. The right panel shows the difference in prognostic scores between the
index patient and matched controls, ie, controls with prognostic scores within the caliper
TABLE 4 Rate of days hospitalized post-liver transplant: comparison of proposed method with
traditional baseline and time-dependent Cox models
Model Equation Parameter RR 95% CI P Value
I: Proposed Method (10) 𝛽⋆ 2.90 (1.69-4.97) < .001
II: Time-dependent Adjustment Covariates (17) 𝜃II 1.44 (1.35-1.53) < .001
III: Baseline Adjustment Covariates (18) 𝜃III 3.17 (3.01-3.35) < .001
Abbreviations: CI, confidence interval; RR, rate ratio.
patients that have developed ESRD, but this comparison is to patients without ESRD that have the same lab values and
hospitalization history at time t. By contrast, adjusting only for baseline values of factors associated with the development
of ESRD (Model III) estimates that patients that develop ESRDhave a days hospitalized rate 3.2 times higher than patients
that do not have ESRD at time t and were similar at transplant. This comparison demonstrates how use of the proposed
method balances the opposing biases of overadjustment and underadjustment. As a sensitivity analysis, we also tested
interactions with time since development of ESRD and time of development of ESRD, but no significant variations in the
effect ESRD development were found (both rate ratios ≈ 1, P = .23 and P = .68, respectively).
5 DISCUSSION
In this report, we lay out a two-stage method for estimating the effect of time-dependent treatments on recurrent events
using an extension of the method of sequential stratification. The method proposed is partly conditional in the sense that
information up until treatment time, s, is used in the prognostic model, but the final model for 𝜇⋆i𝑗 (t; s) does not condition
on covariates after s. A purely conditional model (eg, Anderson and Gill1), which would include covariate information
on [s, s+ t), would tend to dampen the effect of treatment because it would require comparison subjects to have the same
history at the time of treatment. A marginal analysis such as that of Lin et al,4 on the other hand, would exaggerate the
effect of treatment because since treatment depends on the history, subjects that receive treatment at time s may differ
from those that do not. Our method ensures subjects are similar up to s through conditioning and is marginal thereafter,
so that the posttreatment comparison averages over the treatment-free experience of the matched controls.
Note that there are two practical considerations to consider when applying this method. First, to fit the prognostic
model, there needs to be sufficient observed time-at-risk prior to treatment and a sufficient number of events prior to
treatment. In the repeatedmeasures setting, this is generally not a concern since a given subject can havemultiple events;
however, if the recurrent event is rare and many subjects never experience the recurrent event or don't experience their
first recurrent event prior to treatment, this must be considered. Second, there must be enough strata for sequential
stratification to be appropriately applied. In the proposed method, each treated subject forms their own stratum and is
matched to patients with similar prognostic scores at the time of treatment. In theory, this implies that there does not
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need to be large variation in treatment times; however, themethodwas developed for the setting in which subjects receive
treatment at varying times during follow-up, and in the setting in which all patients are treated at the same time (ie, at or
close to baseline) alternative, traditional methods apply.
The biases of the approaches featuring either baseline-covariate-only or fully time-dependent covariate adjustment is
demonstrated in Section 5 in the context of the development of post-liver transplant ESRD in the A2ALL study. While all
the 3 methods produced significant results, the fully time-dependent model, which included a time-dependent indicator
for development of ESRD as well as time-dependent lab values and previous number of days hospitalized (each associated
with renal failure progression), underestimated the effect of ESRD on the rate of days hospitalized by almost half. In con-
trast, the baseline-covariate-only approach overestimated the effect of ESRD development. While in this application the
two traditional models produced bias in opposite directions, this may not always be the case, and the direction of the bias
may depend on themagnitude and direction of association between the time-dependent covariate(s) and the probability of
treatment and the recurrent event rate, the degree ofmodelmisspecification, and the presence of nonlinear link functions.
In addition, the comparison groups for these models are not constructed in a way that gives the desired interpretation, ie,
a comparison of the event rate in the time period following treatment in the presence and absence of treatment.
Note that the outcome chosen in the application was days hospitalized instead of hospital admissions. Analyses of
hospital admissions often ignore the fact that patients are not at risk for hospitalization during the period in which they
are in the hospital. This can be accounted for by removing the duration of hospitalization from the risk set; however, this
step is often ignored. Modeling days hospitalized instead of hospital admissions automatically removes this potential for
error; however, in some situations, hospital admissions may be a more relevant outcome.
As mentioned previously, it follows from the dependence of treatment initiation on the event history that censoring of
matched controls due to treatment would constitute dependent censoring. We have shown that when the treatment is
rare, bias is not substantial, and therefore IPCW to correct for dependent censoring is not necessary. However, for more
common treatments, bias will be induced and therefore some sort of weighting must be done to preserve the unbiased
properties of 𝛽⋆.
The proposed method makes use of the prognostic score to match as yet untreated patients into strata. Another viable
alternative would be propensity matching,23 ie, matching on the probability of receiving treatment. A time-dependent
propensity score has beenproposed byLu24 and could beused in this setting.Our goal, however,was to create a comparison
group that mirrored the treatment-free experience of a subject treated at time s. It was therefore necessary to ensure that
the event trajectories up until s were the same between treated and control subjects, a property that the propensity score
does not preserve. Some combination of prognostic and propensity scores could also be used. Another potential option
would be to hard match on the event counter at the time of treatment initiation, given that it is the strongest predictor of
the pre-treatment event rate. However, we previously investigated this approach and found that prognostic scorematching
performed better. 22
One limitation of the proposedmethod is that it does not account for terminating events that halt all further occurrences
of the recurrent event. The terminal event is often correlated with the recurrent event, and when treated as a censoring
mechanism, can result in dependent censoring. Numerous methods for the simultaneous modeling of recurrent and
terminal events are currently available. Marginal models of recurrent events while subjects are alive have been described
by Cook and Lawless25 and Ghosh and Lin.26 Joint modeling methods where the recurrent and terminal event processes
are linked through a subject-level random effect have been proposed by Liu et al,27 Ye et al,28 Kalbfleisch et al,29 and others.
Development of these methods is currently underway.
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